BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tokumaru Y, Katsuta E, Oshi M, Sporn JC, Yan L, Le L, Matsuhashi N, Futamura M, Akao Y, Yoshida K, Takabe K. High Expression of miR-34a Associated with Less Aggressive Cancer Biology but Not with Survival in Breast Cancer. Int J Mol Sci 2020;21:E3045. [PMID: 32357442 DOI: 10.3390/ijms21093045] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Oshi M, Tokumaru Y, Benesch MG, Sugito N, Wu R, Yan L, Yamada A, Chishima T, Ishikawa T, Endo I, Takabe K. High miR-99b expression is associated with cell proliferation and worse patient outcomes in breast cancer.. [DOI: 10.21203/rs.3.rs-1963644/v1] [Reference Citation Analysis]
2 Ryspayeva D, Halytskiy V, Kobyliak N, Dosenko I, Fedosov A, Inomistova M, Drevytska T, Gurianov V, Sulaieva O. Response to neoadjuvant chemotherapy in breast cancer: do microRNAs matter? Discov Onc 2022;13. [DOI: 10.1007/s12672-022-00507-z] [Reference Citation Analysis]
3 Pan J, Zhou L, Lin C, Xue W, Chen P, Lin J. MicroRNA-34a Promotes Ischemia-Induced Cardiomyocytes Apoptosis through Targeting Notch1. Evid Based Complement Alternat Med 2022;2022:1388415. [PMID: 35265142 DOI: 10.1155/2022/1388415] [Reference Citation Analysis]
4 Tokumaru Y, Oshi M, Huyser MR, Yan L, Fukada M, Matsuhashi N, Futamura M, Akao Y, Yoshida K, Takabe K. Low expression of miR-29a is associated with aggressive biology and worse survival in gastric cancer. Sci Rep 2021;11:14134. [PMID: 34239017 DOI: 10.1038/s41598-021-93681-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Oshi M, Murthy V, Takahashi H, Huyser M, Okano M, Tokumaru Y, Rashid OM, Matsuyama R, Endo I, Takabe K. Urine as a Source of Liquid Biopsy for Cancer. Cancers (Basel) 2021;13:2652. [PMID: 34071230 DOI: 10.3390/cancers13112652] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
6 Gandhi S, Oshi M, Murthy V, Repasky EA, Takabe K. Enhanced Thermogenesis in Triple-Negative Breast Cancer Is Associated with Pro-Tumor Immune Microenvironment. Cancers (Basel) 2021;13:2559. [PMID: 34071012 DOI: 10.3390/cancers13112559] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
7 Tokumaru Y, Oshi M, Patel A, Tian W, Yan L, Matsuhashi N, Futamura M, Yoshida K, Takabe K. Organoids Are Limited in Modeling the Colon Adenoma-Carcinoma Sequence. Cells 2021;10:488. [PMID: 33668713 DOI: 10.3390/cells10030488] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Le L, Tokumaru Y, Oshi M, Asaoka M, Yan L, Endo I, Ishikawa T, Futamura M, Yoshida K, Takabe K. Th2 cell infiltrations predict neoadjuvant chemotherapy response of estrogen receptor-positive breast cancer. Gland Surg 2021;10:154-65. [PMID: 33633972 DOI: 10.21037/gs-20-571] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
9 Oshi M, Angarita FA, Tokumaru Y, Yan L, Matsuyama R, Endo I, Takabe K. High Expression of NRF2 Is Associated with Increased Tumor-Infiltrating Lymphocytes and Cancer Immunity in ER-Positive/HER2-Negative Breast Cancer. Cancers (Basel) 2020;12:E3856. [PMID: 33371179 DOI: 10.3390/cancers12123856] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
10 Oshi M, Newman S, Tokumaru Y, Yan L, Matsuyama R, Endo I, Takabe K. Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients. J Immunol Res 2020;2020:5618786. [PMID: 33457427 DOI: 10.1155/2020/5618786] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
11 Oshi M, Tokumaru Y, Angarita FA, Yan L, Matsuyama R, Endo I, Takabe K. Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer. Cancers (Basel) 2020;12:E3557. [PMID: 33260779 DOI: 10.3390/cancers12123557] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
12 Oshi M, Asaoka M, Tokumaru Y, Angarita FA, Yan L, Matsuyama R, Zsiros E, Ishikawa T, Endo I, Takabe K. Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Cancers (Basel) 2020;12:E3038. [PMID: 33086518 DOI: 10.3390/cancers12103038] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 8.7] [Reference Citation Analysis]
13 Oshi M, Tokumaru Y, Asaoka M, Yan L, Satyananda V, Matsuyama R, Matsuhashi N, Futamura M, Ishikawa T, Yoshida K, Endo I, Takabe K. M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer. Sci Rep 2020;10:16554. [PMID: 33024179 DOI: 10.1038/s41598-020-73624-w] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 16.7] [Reference Citation Analysis]
14 Oshi M, Newman S, Tokumaru Y, Yan L, Matsuyama R, Endo I, Katz MHG, Takabe K. High G2M Pathway Score Pancreatic Cancer is Associated with Worse Survival, Particularly after Margin-Positive (R1 or R2) Resection. Cancers (Basel) 2020;12:E2871. [PMID: 33036243 DOI: 10.3390/cancers12102871] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
15 Oshi M, Newman S, Murthy V, Tokumaru Y, Yan L, Matsuyama R, Endo I, Takabe K. ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer. Cancers (Basel) 2020;12:E2758. [PMID: 32992708 DOI: 10.3390/cancers12102758] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
16 Oshi M, Asaoka M, Tokumaru Y, Yan L, Matsuyama R, Ishikawa T, Endo I, Takabe K. CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer. Int J Mol Sci 2020;21:E6968. [PMID: 32971948 DOI: 10.3390/ijms21186968] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 17.0] [Reference Citation Analysis]
17 Oshi M, Newman S, Tokumaru Y, Yan L, Matsuyama R, Endo I, Nagahashi M, Takabe K. Intra-Tumoral Angiogenesis Is Associated with Inflammation, Immune Reaction and Metastatic Recurrence in Breast Cancer. Int J Mol Sci 2020;21:E6708. [PMID: 32933189 DOI: 10.3390/ijms21186708] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
18 Tokumaru Y, Oshi M, Katsuta E, Yan L, Huang JL, Nagahashi M, Matsuhashi N, Futamura M, Yoshida K, Takabe K. Intratumoral Adipocyte-High Breast Cancer Enrich for Metastatic and Inflammation-Related Pathways but Associated with Less Cancer Cell Proliferation. Int J Mol Sci 2020;21:E5744. [PMID: 32796516 DOI: 10.3390/ijms21165744] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
19 Oshi M, Takahashi H, Tokumaru Y, Yan L, Rashid OM, Nagahashi M, Matsuyama R, Endo I, Takabe K. The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2- Breast Cancer. Cells 2020;9:E1643. [PMID: 32650578 DOI: 10.3390/cells9071643] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 10.7] [Reference Citation Analysis]
20 Gandhi S, Elkhanany A, Oshi M, Dai T, Opyrchal M, Mohammadpour H, Repasky EA, Takabe K. Contribution of Immune Cells to Glucocorticoid Receptor Expression in Breast Cancer. Int J Mol Sci 2020;21:E4635. [PMID: 32629782 DOI: 10.3390/ijms21134635] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]